Earnings Call · Q1 FY2026·2026-05-09

Q1 26EPS -9.44%·Rev n/aQ4 25EPS +100.00%*·Rev n/aQ3 25EPS +60.10%·Rev n/aQ2 25EPS +14.29%·Rev n/a⚠ consensus missing

LIGAND PHARMACEUTICALS INC LGND

Melanie Herman — Head of Investor Relations

Todd Davis — Chief Executive Officer

Octavio Espinoza — Chief Financial Officer

Lauren Hay — Vice President of Portfolio Strategy and Investments

−9.6%1d on move date−9.2% vs SPY3d−5.2%5d−4.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LGND calls or request research access.

More LGND calls Browse calls Request research access